High relapse rate seen at week 72 for patients treated with R1626 combination therapy

Hepatology. 2008 Oct;48(4):1349-50. doi: 10.1002/hep.22593.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antiviral Agents / therapeutic use*
  • Dose-Response Relationship, Drug
  • Drug Synergism
  • Drug Therapy, Combination
  • Hepatitis C / drug therapy*
  • Hepatitis C / prevention & control*
  • Humans
  • Incidence
  • Interferon alpha-2
  • Interferon-alpha / therapeutic use*
  • Nucleosides / therapeutic use*
  • Polyethylene Glycols / therapeutic use*
  • Prodrugs / therapeutic use*
  • Recombinant Proteins
  • Recurrence
  • Ribavirin / therapeutic use*
  • Treatment Outcome

Substances

  • Antiviral Agents
  • Interferon alpha-2
  • Interferon-alpha
  • Nucleosides
  • Prodrugs
  • Recombinant Proteins
  • Polyethylene Glycols
  • Ribavirin
  • peginterferon alfa-2a
  • balapiravir